Insulin Therapy

Overview

Insulin therapy refers to the clinical administration of exogenous insulin — a peptide hormone normally secreted by pancreatic beta cells — to regulate blood glucose concentrations in individuals whose endogenous insulin production or action is impaired. Since its first clinical use in the early 1920s, insulin therapy has remained the cornerstone of management for type 1 diabetes (T1D), where autoimmune destruction of beta cells eliminates endogenous secretion, and is increasingly used in advanced type 2 diabetes (T2D) when oral agents and non-insulin injectables can no longer achieve adequate glycemic control. Insulin exerts its primary effects by binding the insulin receptor, a receptor tyrosine kinase, triggering downstream signaling cascades that promote glucose uptake — particularly in skeletal muscle and adipose tissue — suppress hepatic glucose production, and facilitate glycogen and lipid synthesis. Disruption of these pathways, characterized by reduced insulin-stimulated glucose uptake, accumulation of triacylglycerol, mitochondrial dysfunction, and altered protein metabolism in skeletal muscle, defines the insulin resistance that underpins obesity-related T2D.

Beyond its classical metabolic role, insulin participates in a broader physiological network. It intersects with the leptin and AMPK signaling axes, modulates immune cell homeostasis through epigenetic regulation of CD4+ effector memory T cells, and influences systemic inflammatory tone via cytokines including interleukin-6 and C-C motif chemokine ligand 2. Therapeutic insulin formulations range from rapid-acting analogs used in bolus dosing and closed-loop pump systems to longer-acting basal preparations, and contemporary research is actively exploring novel delivery routes — transdermal, sublingual, oral, and ocular — alongside advanced drug delivery systems designed to achieve glucose-responsive, physiologically appropriate release kinetics.

Focus of Latest Publications

Recent publications have investigated advanced insulin delivery technologies as alternatives to traditional subcutaneous injection. Multiple studies evaluated automated insulin delivery (AID) systems and fully closed-loop insulin delivery compared to standard multiple daily insulin (MDI) injections with continuous glucose monitoring, examining their potential to improve glycemic control in both type 1 and type 2 diabetes. Beyond conventional syringes, researchers developed diverse minimally invasive delivery platforms, including microfluidic jet injections, bubble microneedles for transdermal and sublingual routes, and injectable glucose-responsive hydrogels that sustain insulin release for extended periods—with some formulations maintaining therapeutic glucose control for up to seven days in diabetic animal models. These formulation advances also addressed practical limitations of traditional insulin, including prevention of protein aggregation through amphiphilic chaperone molecules, pH-responsive release mechanisms for oral delivery, and sustained-release profiles that reduce dosing frequency.

The physiological effects of insulin therapy have been examined across diverse patient populations and metabolic states. Studies characterized postprandial insulin dynamics in obesity, revealing substantial individual and sex-specific variation in glucose-insulin responses that correlate with markers of insulin resistance and liver dysfunction. In specific disease contexts, insulin secretion was investigated in relation to genetic risk factors in prediabetes, vagal regulation of insulin release in obese individuals (where vagal activation paradoxically inhibited insulin via nitric oxide-dependent signaling rather than stimulating it), and early markers of insulin secretory defects in young adults with obesity. Researchers also explored insulin's role beyond glucose homeostasis, demonstrating that insulin signaling in immune cells modulates metabolic activity and cellular phenotype in patients with rheumatoid arthritis, and that insulin signaling responses in skeletal muscle remain intact despite obesity and type 2 diabetes.

Clinical investigations addressed insulin therapy in specific populations and disease states. In acute ischemic stroke patients undergoing mechanical thrombectomy, documented long-term insulin use was associated with higher risk of non-home discharge but lower rates of procedure-related complications. Real-world treatment patterns in Hispanic adults with type 2 diabetes showed that insulin use was independently associated with lower odds of achieving glycemic targets (HbA1c ≤7%), likely reflecting preferential prescription to patients with more advanced disease. Additionally, predictive models were developed to identify which pregnant women with gestational diabetes would require insulin therapy, and quality-of-life assessments showed that insulin-treated type 2 diabetes patients face psychosocial and practical challenges despite improved glycemic control.

Combination therapy approaches involving insulin have been evaluated alongside newer pharmacological agents. Studies examined how Amino Acids of different compositions affect both insulin and GLP-1 secretion, with branched-chain Amino Acids stimulating insulin secretion even at low glucose concentrations. In patients receiving basal insulin, adjunctive exenatide enhanced the endogenous GLP-1 secretory response, suggesting interplay between insulin and incretin pathways. semaglutide, a GLP-1 receptor agonist, facilitated insulin dose reduction in adults with type 1 diabetes and obesity, indicating that combination therapy may optimize glycemic control while reducing overall insulin requirements.

Systemic barriers to insulin access and patient experience remain significant clinical concerns. Studies documented that individuals with type 1 diabetes frequently encounter obstacles to acquiring insulin and diabetes devices, with some turning to social media communities for support when healthcare systems fail to meet their needs. These real-world challenges underscore the continued importance of improving not only the efficacy and delivery mechanisms of insulin therapy, but also ensuring equitable and reliable access to this essential medication.

Key Publications

• NEWJan Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 Diabetes. (Diabetes technology & therapeutics, 2026, PMID 42381171): "Despite insulin therapy, T1D can lead to diabetic ketoacidosis (DKA), microvascular and macrovascular complications, hypoglycemia, and increased mortality, placing a substantial financial burden on European health care systems."
• NEWJun Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. (The AAPS journal, 2026, PMID 42373916): "The resulting MWhd values were several-fold greater than the corresponding monomeric MW of the glucagon-like peptide-1/2 (GLP-1/2) analogs, insulin analogs, and the monoclonal antibodies (mAbs) infliximab and bevacizumab, indicating varying degrees of oligomerization."
• NEWJul Global and Partitioned Polygenic Risk Scores: Associations With Pathophysiology and Incidence of Type 2 Diabetes in People With Prediabetes. (Diabetes, 2026, PMID 42330299): "Type 2 diabetes partitioned polygenic risk scores (pPRS) are related to their physiological impact on insulin secretion and sensitivity."
• May Vagal activation inhibits insulin release through neuronal nitric oxide synthase in obese male mice. (Science signaling, 2026, PMID 42189938): "As expected, the plasma concentration of insulin was increased by vagal activation in mice expressing the excitatory DREADD hM3Dq (M3 mice) and decreased by vagal inactivation in mice expressing inhibitory DREADD hM4Di (M4 mice)."
• May The 1-hour plasma glucose as a specific marker for early-phase insulin secretory defects in young adults with obesity. (Diabetes research and clinical practice, 2026, PMID 42184890): "To determine whether 1-hour plasma glucose (1-h PG) during an OGTT outperforms other glycemic markers (FPG, 0.5-h PG, 2-h PG, HbA1c) in identifying impairments in insulin secretion, sensitivity, and β-cell compensation."
• May Insulin enables acquisition of the IL7R+ memory phenotype in PD1+ T cells in RA tissues. (Cell death & disease, 2026, PMID 42185247): "Insulin signaling regulates cellular metabolism in an epigenetic manner, but its role in the immune cell homeostasis remains unknown."
• May Heterogeneity in postprandial glucose-insulin and triacylglycerol dynamics and associations with plasma metabolome and body composition in obesity. (American journal of physiology. Endocrinology and metabolism, 2026, PMID 42166654): "...individual variation in postprandial response dynamics in key hormones and metabolites such as insulin, glucose, and triacylglycerols (TAGs)."
• May Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis. (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2026, PMID 42159385): "Among those who started antidiabetic agents after alpelisib, 81.8% were prescribed metformin and 44% insulin."
• May Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol. (BMJ open, 2026, PMID 42156154): "Insulin injections improve HbA1c but can lead to problematic hypoglycaemia."
• May National trends and comparative outcomes of insulin versus non-insulin therapy in acute ischemic stroke patients treated with mechanical thrombectomy: a retrospective cohort study using the national inpatient sample. (Neurosurgical review, 2026, PMID 42156589): "Patients were categorized by documented long-term insulin use versus no such documentation, as a proxy for diabetes severity and disease burden."